Innovative Automation Mytos specializes in automated human cell manufacturing using robotic systems, providing scalable solutions for cell therapy production and drug testing. This positions the company to further expand its automation offerings to biotech firms seeking efficient, high-throughput cell cultivation.

Strong Funding Backing With a recent $19 million Series A investment led by prominent venture firms like Buckley Ventures, IQ Capital, and Wing VC, Mytos has substantial financial resources to accelerate product development, market expansion, and partnership opportunities, making it attractive for investors and collaborators.

Strategic Partnerships Mytos has formed collaborations with leading biotech organizations such as Aspen Neuroscience and StemSight, indicating a growing demand for automated cell production in advanced cell therapies. This opens up opportunities to offer tailored automation solutions for emerging therapeutic areas.

Market Focus & Growth Operating in the rapidly advancing biotechnology research sector with applications in regenerative medicine and drug discovery, Mytos targets a expanding market for automated cell manufacturing, presenting sales opportunities with biotechs and pharmaceutical companies looking to scale their therapies faster.

Technology & Expertise Equipped with advanced tech stacks including CUDA, Python, and Linux, and supported by a skilled team of engineers and scientists, Mytos can meet the complex automation needs of biotech clients, providing scope for customized solutions in process automation and advanced cell therapy development.